NEW YORK (GenomeWeb) – GenMark Diagnostics said after the close of the market on Tuesday that revenues for its fourth quarter rose 51 percent year over year. 

The Carlsbad, Calif.-based company posted revenues of $9.8 million for the three months ended Dec. 31, 2014, up from $6.5 million in the year-ago quarter, beating the consensus Wall Street estimate of $9.1 million. During the recently completed quarter, GenMark placed 38 XT-8 analyzers in end-user laboratories for a total installed base of 540 instruments in the US as of the end of 2014. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.